Salmeterol
| Evidence Level: L1 | Predicted Indications: 7 |
Table of Contents
Salmeterol: From Asthma to Bronchitis
One-Sentence Summary
Salmeterol is a long-acting beta2-agonist, originally used (in the combination product Seffalair Spiromax) for the regular treatment of asthma. The TxGNN model predicts it may be effective for bronchitis, with 9 clinical trials and 20 publications compiled for this prediction. The evidence mostly concerns COPD with chronic bronchitis, where salmeterol (alone or with fluticasone) is already an established therapy.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting beta2 agonists |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L1 |
| EU Market Status | Cancelled only (no currently valid authorization) |
| Number of Authorizations | 1 (cancelled) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Salmeterol is a long-acting beta2-adrenoceptor agonist. It relaxes bronchial smooth muscle by raising intracellular cAMP, and it may also improve mucociliary clearance. Detailed mechanism-of-action data were not available in the data compiled for this report, so this description reflects general pharmacology and the mechanistic rationale in the evidence.
Asthma and chronic bronchitis (the chronic bronchitis phenotype of COPD) are both obstructive airway diseases. Both involve airway narrowing, and bronchodilation is a cornerstone of treatment for each. A small study of 14 patients with mild-to-moderate chronic bronchitis examined salmeterol’s acute effect on mucociliary and cough clearance. Salmeterol, alone or combined with fluticasone, is already used in COPD. The prediction is therefore a close extension of the approved respiratory use rather than a distant repurposing.
Caveat: most trials enrolled COPD patients in general, not bronchitis specifically. Several of them did not test salmeterol as the main agent, but used it as an active comparator.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00268177 | Phase 3 | Completed | 130 | 13-week placebo-controlled study of salmeterol/fluticasone 50/500 on airway inflammation in COPD |
| NCT02173691 | Phase 3 | Completed | 584 | Six-month comparison of tiotropium, salmeterol and placebo in COPD; bronchodilator efficacy and safety |
| NCT00064402 | Phase 3 | Completed | 741 | Arformoterol vs placebo and active control in COPD over 12 weeks; likely salmeterol as active control |
| NCT00064415 | Phase 3 | Completed | 799 | 12-month safety study of arformoterol in COPD; salmeterol likely the active control |
| NCT00269087 | Phase 3 | Completed | 122 | 56-week long-term safety study of salmeterol/fluticasone (GW815SF) 50/500 in COPD (chronic bronchitis, emphysema) |
| NCT00269126 | Phase 3 | Completed | 150 | 18-week comparison of two medicines in COPD with breathing tests and diary cards |
| NCT00403286 | Phase 2 | Completed | 457 | Dose-finding of fluticasone/formoterol against Advair (fluticasone/salmeterol) in COPD |
| NCT01361984 | Phase 4 | Unknown | 20 | Nebulized arformoterol vs salmeterol dry-powder inhaler in COPD |
| NCT00233051 | N/A | Terminated | 20 | Sputum gene expression as a biomarker of drug response in COPD |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 17557771 | 2007 | RCT | Thorax | Effect of salmeterol/fluticasone on airway inflammation in COPD |
| 17196106 | 2006 | Meta-analysis | Respiratory Research | Salmeterol improved clinically relevant outcomes in COPD compared with placebo/usual therapy |
| 15970448 | 2006 | Clinical study | Pulm Pharmacol Ther | Acute effect of salmeterol vs placebo on mucociliary and cough clearance in 14 patients with chronic bronchitis |
| 12970006 | 2003 | Clinical trial | Chest | Fluticasone 250/salmeterol 50 in the Diskus vs placebo and the single agents in COPD |
| 19124357 | 2008 | Clinical study | Ther Adv Respir Dis | One-year safety and tolerance of arformoterol and salmeterol in COPD |
| 19210134 | 2009 | Cohort | Curr Med Res Opin | Healthcare use and costs in chronic bronchitis patients starting fluticasone/salmeterol vs other inhaled maintenance therapies |
| 15329047 | 2004 | Review | Drugs | Review of salmeterol/fluticasone in COPD; approved in the US for COPD with chronic bronchitis and in the EU for severe COPD |
| 25515181 | 2015 | Guideline | Basic Clin Pharmacol Toxicol | Finnish guideline on diagnosis and pharmacotherapy of stable COPD |
| 9916607 | 1998 | Open-label study | Clin Ther | Salmeterol vs oral theophylline in mild-to-moderate COPD |
| 12236842 | 2002 | Pharmacology study | Br J Clin Pharmacol | Antagonism of long-acting beta2-agonism; relevance to LABA use with inhaled corticosteroids |
EU Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| EMEA/H/C/004881 (cancelled) | Seffalair Spiromax | Not specified | Seffalair Spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled… |
Safety Considerations
- Contraindication signals from the knowledge graph (derived from drug-disease links, not label text): hypertension, long QT syndrome, epilepsy, hyperglycaemia, herpes simplex virus keratitis, hypopituitarism and other pituitary hormone deficiencies, thymus gland disease and osteoporosis. These should be verified against the product label.
- Drug interactions: 600 interactions were recorded. Examples:
- Major: clarithromycin.
- Moderate: epinephrine, several antidiabetic agents (acarbose, canagliflozin, dapagliflozin, empagliflozin, alogliptin, chlorpropamide, albiglutide, dulaglutide), famotidine, dolasetron, diethylpropion and isometheptene.
- Minor: corticosteroids such as hydrocortisone, dexamethasone, budesonide and beclomethasone.
- Class warning: Cochrane reviews of regular LABA use in asthma report a serious-adverse-event signal, particularly without an inhaled corticosteroid. Salmeterol should be used with an inhaled corticosteroid in asthma.
Please refer to the SmPC for the full warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale:
- Several completed Phase 3 trials and RCTs support salmeterol and salmeterol/fluticasone in COPD, including the chronic bronchitis phenotype, and the drug class is already established there. However, the evidence concerns COPD rather than bronchitis as a standalone condition, and the current EU authorization is cancelled.
To proceed, the following is needed:
- Mechanism of action data confirmed from DrugBank.
- Warnings and contraindications from the SmPC.
- Clarification of the exact bronchitis population (chronic bronchitis within COPD vs. acute bronchitis), since the evidence does not address acute bronchitis.
- Confirmation of the regulatory pathway, given that the only EU license is cancelled.
- A safety plan covering LABA use with inhaled corticosteroids, cardiovascular risk, and interactions with strong CYP3A4 inhibitors such as clarithromycin.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.